267 related articles for article (PubMed ID: 24529554)
21. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
22. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
[TBL] [Abstract][Full Text] [Related]
23. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity.
Wang Y; Xu H; Zheng X; Wei H; Sun R; Tian Z
Cell Mol Immunol; 2007 Oct; 4(5):377-82. PubMed ID: 17976318
[TBL] [Abstract][Full Text] [Related]
24. Influence of dendritic cells on biological activity of the homologous CIK cells and its anti-leukemia effect in vitro.
Wei XC; Zhai XH; Han XR; Yang DD; Wang QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):946-51. PubMed ID: 20723306
[TBL] [Abstract][Full Text] [Related]
25. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
[TBL] [Abstract][Full Text] [Related]
26. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
Front Immunol; 2021; 12():731767. PubMed ID: 34691037
[TBL] [Abstract][Full Text] [Related]
27. [The effect of tumor-dendritic cell fusion vaccines on the cytotoxicity of CIK/NK cells from cord blood].
Li Y; Huang SL; Wu YF; Wei J; Meng Y; Zhou DH; Bao R
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):269-72. PubMed ID: 15949286
[TBL] [Abstract][Full Text] [Related]
28. Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells.
Valgardsdottir R; Capitanio C; Texido G; Pende D; Cantoni C; Pesenti E; Rambaldi A; Golay J; Introna M
Exp Hematol; 2014 Dec; 42(12):1013-21.e1. PubMed ID: 25201755
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of human cord blood natural killer cells is enhanced by recombinant interleukin-15.
Saghafi S; Pourfathollah AA; Kheirandish M; Azimdoust A; Behnia M; Shahjahani M; Moin M
Iran J Allergy Asthma Immunol; 2010 Jun; 9(2):69-77. PubMed ID: 20683100
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
33. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
[TBL] [Abstract][Full Text] [Related]
34. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
[TBL] [Abstract][Full Text] [Related]
35. [Expansion of CIK/NK cells from cord blood by using different combinations of stem cell factor, FLT3 ligand and interleukin 2, 7, 15 in vitro].
Li Y; Huang SL; Wu YF; Wei J; Bao R; Zhou DH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):350-4. PubMed ID: 15228665
[TBL] [Abstract][Full Text] [Related]
36. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2012 Jun; 12(6):673-84. PubMed ID: 22500889
[TBL] [Abstract][Full Text] [Related]
37. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
38. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
[TBL] [Abstract][Full Text] [Related]
39. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
40. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation.
Luevano M; Daryouzeh M; Alnabhan R; Querol S; Khakoo S; Madrigal A; Saudemont A
Hum Immunol; 2012 Mar; 73(3):248-57. PubMed ID: 22234167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
